Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

1. Kecmanović D. Shizofrenija. Psihijatrija, II prerađeno i dopunjeno izdanje, Medicinska knjiga Beograd- Zagreb, 1983; 355-408.Search in Google Scholar

2. Lewis S, Escalona R, Keith S. Phenomenology of Schizophrenia, Kaplan & Sadock’s comprehensive textbook of psychiatry, ninth edition, 2009; 1: 1433-1451.Search in Google Scholar

3. World Health Organization: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, World Health Organization, Geneva, 1992.Search in Google Scholar

4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.Search in Google Scholar

5. Möller HJ.Development of DSM-V and ICD-11: tendencies and potential of new classifications in psychiatry at the current state of knowledge. Psychiatry Clin Neurosci. 2009; 63(5): 595-612.10.1111/j.1440-1819.2009.02020.xSearch in Google Scholar

6. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 2009; 63: 257-265.10.1111/j.1440-1819.2009.01945.xSearch in Google Scholar

7. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B, Thomas EA.Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008; 1239: 235-48.10.1016/j.brainres.2008.08.023Search in Google Scholar

8. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev. 1995; 8(1): 131-45.10.1128/CMR.8.1.131Search in Google Scholar

9. Müller N, Riedel M, Gruber R, Manfred A. and Schwarz M. The Immune System and Schizophrenia- An Integrative View. Ann NY Acad Sci. 2000; 917: 456-67.10.1111/j.1749-6632.2000.tb05410.xSearch in Google Scholar

10. Cazzullo CL, Trabattoni D, Saresella M, Annoni G, Arosio B, Clerici M. Research on psychoimmunology. World J Biol Psychiatry. 2003; 4(3): 119-23.10.1080/15622970310029905Search in Google Scholar

11. Korn T, Anderson AC, Bettelli E, Oukka M. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol. 2007; 191(1-2): 51-60.10.1016/j.jneuroim.2007.09.009Search in Google Scholar

12. Abbas A, Lichtman AH, Pillai S. Cellular and Molecular Immunology, 6th Edition, Saunders, Elsevier, Philadelphia, USA, 2007.Search in Google Scholar

13. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD, Zurawski G, Leach MW, Gorman DM, Rennick DM. IL-25 induces IL-4, IL-5, and IL-13 and Th2- associated pathologies in vivo. Immunity. 2001; 15(6): 985-95.10.1016/S1074-7613(01)00243-6Search in Google Scholar

14. Müller N, Schwarz MJ. Immune System and Schizophrenia. Curr Immunol Rev. 2010; 6(3): 213-220.10.2174/157339510791823673297154821057585Search in Google Scholar

15. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008; 172(1): 146-55.10.2353/ajpath.2008.070690218961518156204Search in Google Scholar

16. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.10.1038/nm155117290272Search in Google Scholar

17. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin Dev Immunol. 2007; 2007: 89195.10.1155/2007/89195225366818317534Search in Google Scholar

18. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24: 179-189.10.1016/j.immuni.2006.01.00116473830Search in Google Scholar

19. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry 2009; 10(2): 127- 155.10.1080/1562297090289898019396704Search in Google Scholar

20. Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, Hampel H. Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol. 2011; 95(4): 686-702.10.1016/j.pneurobio.2011.05.00621664943Search in Google Scholar

21. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol Psychiatry. 2011; 70(7): 663-71.10.1016/j.biopsych.2011.04.013407130021641581Search in Google Scholar

22. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012; 46(11): 1421-6.10.1016/j.jpsychires.2012.08.01622974591Search in Google Scholar

23. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013; 147(1): 103-9.10.1016/j.schres.2013.03.02723602340Search in Google Scholar

24. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. Psychoneuroendocrinology. 2015; 56: 143-7.10.1016/j.psyneuen.2015.03.00325827958Search in Google Scholar

25. Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev. 1997; 10(4): 742-80.10.1128/CMR.10.4.7421729439336671Search in Google Scholar

26. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett. 2002; 82 (1-2): 85-91.10.1016/S0165-2478(02)00023-8Search in Google Scholar

27. Coomes SM, Moore BB. Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation.Transplantation. 2010; 90 (11): 1139-44.10.1097/TP.0b013e3181efd018Search in Google Scholar

28. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem. 2010; 147(6): 781-92.10.1093/jb/mvq043Search in Google Scholar

29. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.10.1038/nature04753Search in Google Scholar

30. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 2006; 441: 231-4.10.1038/nature04754Search in Google Scholar

31. Massague J. TGF beta signaling: receptors, transducers, and Mad proteins. Cell. 1996; 85: 947-950.10.1016/S0092-8674(00)81296-9Search in Google Scholar

32. Krieglstein K, Zheng F, Unsicker K, Alzheimer C. More than being protective: functional roles for TGF-β/activin signaling pathways at central synapses. Trends Neurosci. 2011; 3 4(8): 421-9.10.1016/j.tins.2011.06.00221742388Search in Google Scholar

33. Sun M, Gewirtz JC, Bofenkamp L, Wickham RJ, Ge H, O’Connor MB. Canonical TGF-beta signaling is required for the balance of excitatory/inhibitory transmission within the hippocampus and prepulse inhibition of acoustic startle. J Neurosci. 2010; 30(17): 6025-35.10.1523/JNEUROSCI.0789-10.2010663259620427661Search in Google Scholar

34. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest. 2006; 116: 3060-9.10.1172/JCI27341162612717080199Search in Google Scholar

35. Ueberham U, Ueberham E, Gruschka H, Arendt T. Altered subcellu- lar location of phosphorylated Smads in Alzheimer’s disease. Eur J Neurosci. 2006; 24: 2327-2334.10.1111/j.1460-9568.2006.05109.x17074053Search in Google Scholar

36. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005; 37: 275-281.10.1038/ng1511Search in Google Scholar

37. Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L,Tomkiewicz A,Sedlaczek P,Kiejna A,Beszłej JA. Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia. Neuropsychiatr Dis Treat.2015; 11: 575-84.Search in Google Scholar

38. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A. 2007; 104: 10164-9.10.1073/pnas.0703806104Search in Google Scholar

39. Dow AL, Russell DS, Duman RS. Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models. J Neurosci. 2005; 25: 4908-16.10.1523/JNEUROSCI.5155-04.2005Search in Google Scholar

40. Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M, Inokuchi K. Activin in the brain modulates anxiety-related behavior and adult neurogenesis. PLoS One. 2008; 3(4): e1869.10.1371/journal.pone.0001869Search in Google Scholar

41. Zheng F, Adelsberger H, Müller MR, Fritschy JM, Werner S, Alzheimer C. Activin tunes GABAergic neurotransmission and modulates anxiety-like behavior. Mol Psychiatry. 2009; 14: 332-346.10.1038/sj.mp.4002131Search in Google Scholar

42. Kitazawa K, Tada T. Elevation of transforming growth factor-beta 1 level in cerebrospinal fluid of patients with communicating hydrocephalus after subarachnoid hemorrhage. Stroke. 1994; 25(7): 1400-4.10.1161/01.STR.25.7.1400Search in Google Scholar

43. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson’s disease. Neurosci Lett. 1995; 193(2): 129-32.10.1016/0304-3940(95)11686-QSearch in Google Scholar

44. Peterson PK, Chao CC, Hu S, Thielen K, Shaskan EG. Glioblastoma, transforming growth factor-beta, and Candida meningitis: a potential link. Am J Med. 1992; 92(3): 262-4.10.1016/0002-9343(92)90075-MSearch in Google Scholar

45. Vawter MP, Dillon-Carter O, Issa F, Wyatt RJ, Freed WJ. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology. 1997; 16(1): 83-710.1016/S0893-133X(96)00143-1Search in Google Scholar

46. Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beveren NJ, Drexhage HA. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol. 2011; 14(6): 746-55.10.1017/S146114571000165321255481Search in Google Scholar

47. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, Leonard BE. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(7): 1129-34.10.1016/j.pnpbp.2004.05.04715610925Search in Google Scholar

48. Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, Takeda M, Kunugi H, Itakura M, Ohmori T. TGFBR2 gene expression and genetic association with schizophrenia. J Psychiatr Res. 2008; 42(6): 425-32.10.1016/j.jpsychires.2007.04.00217560608Search in Google Scholar

49. Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011; 132(1): 96-110. 10.1016/j.pharmthera.2011.06.00321704074Search in Google Scholar

50. El Kissi Y, Samoud S, Mtiraoui A, Letaief L, Hannachi N, Ayachi M, Ali BB, Boukadida J. Increased Interleukin-17 and decreased BAFF serum levels in drug-free acute schizophrenia. Psychiatry Res. 2015; 225(1-2): 58-63.10.1016/j.psychres.2014.10.00725453636Search in Google Scholar

51. Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N, Velligan D, Walss-Bass C. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res. 2013; 151 (1-3): 29-35.10.1016/j.schres.2013.10.01924210870Search in Google Scholar

52. Ding M, Song X, Zhao J, Gao J, Li X, Yang G, Wang X, Harrington A, Fan X, Lv L. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry.2014; 51: 78-82.10.1016/j.pnpbp.2014.01.00124447943Search in Google Scholar

53. Tourjman V, Kouassi É, Koué MÈ, Rocchetti M, Fortin- Fournier S, Fusar-Poli P, Potvin S. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. 2013; 151(1-3): 43-7.10.1016/j.schres.2013.10.01124200418Search in Google Scholar

54. Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res. 2010; 122(1-3): 38-42.10.1016/j.schres.2010.07.001293342420659789Search in Google Scholar

55. Frydecka D, Misiak B, Beszlej JA, Karabon L, Pawlak- Adamska E, Tomkiewicz A, Partyka A, Jonkisz A, Kiejna A. Genetic variants in transforming growth factor-_ gene (TGFB1) affect susceptibility to schizophrenia. Mol Biol Rep. 2013; 40(10): 5607-14.10.1007/s11033-013-2662-8382428924065520Search in Google Scholar

56. Falk S, Wurdak H, Ittner LM, Ille F, Sumara G, Schmid MT, Draganova K, Lang KS, Paratore C, Leveen P, Suter U, Karlsson S, Born W, Ricci R, Gotz M, Sommer L. Brain areaspecific effect of TGF-beta signaling on Wntdependent neural stem cell expansion. Cell Stem Cell. 2008; 2(5): 472-483.10.1016/j.stem.2008.03.00618462697Search in Google Scholar

57. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011; 25(2): 181-213.10.1016/j.bbi.2010.10.01520970492Search in Google Scholar

58. Kalkman HO. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol Ther. 2009; 121(1): 115-22.10.1016/j.pharmthera.2008.11.00219046988Search in Google Scholar

59. Krieglstein K, Suter-Crazzolara C, Fischer WH, Unsicker K. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J. 1995; 14(4): 736-742.10.1002/j.1460-2075.1995.tb07052.x3981397882977Search in Google Scholar

60. Mathieu P, Piantanida AP, Pitossi F. Chronic expression of transforming growth factor-beta enhances adult neurogenesis. Neuroimmunomodulation. 2010; 17(3): 200-1.10.1159/00025872320134202Search in Google Scholar

61. Dobolyi A, Vincze C, Pal G, Lovas G. The neuroprotective functions of transforming growth factor beta proteins. Int J Mol Sci 2012; 13(7): 8219- 58. 10.3390/ijms13078219343023122942700Search in Google Scholar